Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company developing NK cell–based therapies for autoimmune diseases and cancers. This news page aggregates company-issued updates and third-party coverage so readers can follow how Artiva’s AlloNK program and broader pipeline progress over time.
Artiva’s announcements frequently focus on AlloNK (AB-101), an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. News items describe clinical data from Phase 1 and 2 trials in B-cell driven autoimmune diseases such as refractory rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis, including safety, tolerability and translational findings.
Investors and followers of ARTV can use this feed to track key corporate developments, including FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis, selection of RA as the lead indication, enrollment progress across company-sponsored and investigator-initiated trials, and participation in healthcare and investor conferences. Financial results releases provide additional context on research and development spending, cash runway and other operating metrics, as reported in Artiva’s quarterly updates.
Coverage may also reference Artiva’s CAR-NK pipeline targeting solid and hematologic cancers, its strategic relationship with GC Cell for NK cell manufacturing technology, and governance or equity incentive plan updates disclosed through SEC filings. By reviewing the latest ARTV news, readers can follow how Artiva’s NK cell therapy programs evolve, how clinical data mature, and how the company communicates its strategy for addressing unmet needs in autoimmune disease and oncology.
Artiva Biotherapeutics (Nasdaq: ARTV) announced that management will participate in investor conferences in November 2025 and will offer live webcasts and replays.
Key events: a fireside chat at TD Cowen's Immunology & Inflammation Summit (Virtual) on Wednesday, November 12, 2025 at 11:30 a.m. ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 12:00 p.m. GMT. Management is available for investor meetings for registered attendees. Live webcasts will be accessible via the Investors section on Artivabio.com, with replay available for 90 days after each event.
Artiva Biotherapeutics (Nasdaq: ARTV) prioritized refractory rheumatoid arthritis (RA) as the lead indication for AlloNK (AB-101) and announced that the U.S. FDA granted Fast Track Designation for AlloNK in refractory RA in combination with rituximab. The company reported >20 patients treated with AlloNK plus monoclonal antibody therapy at 1 billion and 4 billion cell doses across multiple autoimmune indications.
Emerging translational and safety data are expected in mid-November; clinical response data from >15 refractory RA patients are expected in 1H 2026. FDA interactions are planned in 1H 2026 to discuss a potential pivotal trial.
Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotech company focused on cell therapies for autoimmune diseases and cancers, will participate in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.
The presentation will be accessible through a live webcast in the "Investors" section of Artivabio.com, with the replay available for 90 days after the event. Management will also be available for meetings with registered conference attendees.
Artiva Biotherapeutics (NASDAQ:ARTV) has reported significant progress in its clinical trials for AlloNK® therapy in autoimmune diseases during Q2 2025. The company has treated over a dozen patients across multiple sites, with the first patient receiving AlloNK + rituximab in their global Phase 2a basket trial for various autoimmune conditions.
The company ended Q2 2025 with $142.4 million in cash and investments, providing runway into Q2 2027. Financial results showed R&D expenses of $17.9 million and a net loss of $21.3 million. Artiva plans to present initial safety and translational data by year-end 2025, along with announcing their lead indication, followed by clinical response data in 1H2026.
ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.
Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.
Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on June 4, 2025, at 9:20 a.m. EDT. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for 90 days afterward. Additionally, the management team will be available for meetings with registered conference attendees.
Artiva Biotherapeutics (NASDAQ: ARTV) reported its Q1 2025 financial results and business updates. The company announced IND clearance and initiation of a global basket trial exploring AlloNK® + rituximab in multiple autoimmune conditions, marking the first allogeneic cell therapy trial for rheumatoid arthritis and Sjögren's disease in the U.S. The company ended Q1 2025 with $166.0 million in cash, extending runway into Q2 2027.
Key financial metrics include R&D expenses of $17.1 million (up from $11.2M in Q1 2024), G&A expenses of $5.1 million (up from $3.6M), and a net loss of $20.3 million (increased from $14.0M). The company's B-NHL trial data showed promising results comparable to approved auto-CAR-T therapies. Initial safety and translational data are expected by year-end 2025, with clinical response data in the lead indication planned for 1H2026.
Artiva Biotherapeutics announced new data presentations for their AlloNK® cell therapy at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans this May.
Key highlights:
- New longer-term Phase 1/2 data shows promising results for AlloNK® combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma
- Treatment demonstrated prolonged response duration, deep B-cell depletion, and well-tolerated safety profile
- Results support AlloNK's potential for treating B-cell driven diseases in community settings
Two poster presentations are scheduled:
- May 13: AlloNK® Cell Therapy ± Rituximab in Patients with Non-Hodgkin Lymphoma
- May 15: AlloNK manufacturing process scalability and consistency
The presentations highlight Artiva's progress in developing accessible cell therapies for autoimmune diseases and cancers. Abstracts are available on the ASGCT website, with poster copies to be shared on Artiva's website after the presentations.
Artiva Biotherapeutics (ARTV) has appointed Dr. Subhashis Banerjee as Chief Medical Officer, succeeding Dr. Thorsten Graef who will continue as a strategic advisor. Dr. Banerjee brings over 20 years of clinical development experience in autoimmune diseases, previously serving as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb and SVP of Clinical Development at VYNE Therapeutics.
The appointment strengthens Artiva's focus on developing their AlloNK® program for B-cell driven autoimmune diseases. Dr. Banerjee's expertise includes development of blockbuster therapies like Humira®, Taltz®, Orencia®, and Sotyktu®. The company has also expanded its development team with key appointments including David Moriarty as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics.